Age-related macular degeneration is an eye condition that harms central vision needed for reading and recognizing faces. Early symptoms of age-related macular degeneration can include blurred or distorted central vision and trouble seeing in low light. It mainly affects adults over 50, and vision changes can progress slowly or sometimes faster over years. AMD does not cause total blindness, and many people live long lives, but advanced stages can severely limit daily tasks. Treatment depends on the type: injections for “wet” AMD, lifestyle steps and vitamins for some “dry” AMD, and low-vision tools to support day-to-day life.
Overview
Age related macular degeneration 14Symptoms
Early symptoms of age-related macular degeneration include blurred or dim central vision and needing brighter light for reading. Straight lines may look wavy, and faces seem harder to recognize. Sudden central vision loss or a dark spot needs urgent care.
Outlook and prognosis
Many people with age-related macular degeneration keep side vision and remain independent, especially with early detection and treatment. Modern anti-VEGF eye injections, monitoring, and low-vision tools can slow central vision loss. Outlook varies by type and stage.
Causes and risk factors
Age-related macular degeneration arises from aging changes in the retina, with oxidative stress and inflammation. Risk increases with family history and genetic variants, white ethnicity, and age. Smoking, high blood pressure, obesity, poor diet, and sun exposure further raise risk.
Genetic influences
Genetics play a major role in Age related macular degeneration 14; several inherited variants strongly increase risk. Family history raises the chance of developing it earlier or more severely. Still, lifestyle and environmental factors also influence onset and progression.
Diagnosis
Age-related macular degeneration is diagnosed during a dilated eye exam. Doctors check the macula and retina, often with optical coherence tomography. Fluorescein angiography or OCT angiography may be used to confirm type and guide treatment.
Treatment and drugs
Treatment for age-related macular degeneration focuses on protecting vision and slowing changes. For wet AMD, eye injections with anti-VEGF medicines and, at times, laser therapy can help. For dry AMD, tailored low-vision aids, lifestyle changes, and specific vitamin/mineral supplements are often used.
Symptoms
Age related macular degeneration 14 affects the sharp, central part of sight, so tasks like reading, recognizing faces, and seeing fine detail can become harder. Early symptoms of Age related macular degeneration 14 may include blurry or distorted central vision, trouble in dim lighting, or a small gray patch that seems to sit in the middle of what you look at. Changes can come on slowly, but some people notice a sudden shift, especially if fluid leaks under the retina. Symptoms vary from person to person and can change over time.
Central vision starts to look fuzzy, making small print or fine detail harder to see. You may find you need more light or bigger font to read. With Age related macular degeneration 14, the blur usually sits in the center, not the edges.
Straight edges, like door frames or lines of text, can look wavy or bent. This distortion can make reading or judging steps tricky. It often becomes more noticeable on patterns like window blinds.
A gray, dark, or empty spot can appear in the middle of what you look at. This spot may grow over time or shift slightly as you move your eyes. People with Age related macular degeneration 14 often notice it when trying to read or recognize faces.
Words can fade, jump, or seem missing in the center of the page. Longer reading sessions may cause eye strain or require frequent breaks. Many with Age related macular degeneration 14 turn to audiobooks or e-readers with larger text.
How people usually first notice Age related macular degeneration 14?
Many people first notice age-related macular degeneration when straight lines on a page look wavy, letters blur, or there’s a gray or dark smudge right in the center of what they’re trying to read or see, while side vision stays clear. You might find yourself needing brighter light, struggling with faces, or taking longer to adapt when moving from bright to dim rooms, especially after age 55 to 60. Often an eye exam reveals early changes before symptoms are obvious, so routine dilated checks or imaging tests like OCT can catch the first signs of age-related macular degeneration even when vision still seems “fine.”
Types of Age related macular degeneration 14
Age related macular degeneration 14 is a rare inherited form of macular degeneration caused by changes in a single gene, leading to early and progressive damage to the central retina. Unlike general age-related macular degeneration, this genetic type can appear earlier in life and may run strongly in families. Clinicians often describe them in these categories: disease variants linked to the specific gene change and how quickly vision declines. Knowing the types of Age related macular degeneration 14 can help people and clinicians recognize patterns and plan monitoring.
Early-onset variant
Symptoms start in childhood or young adulthood with trouble reading fine print and seeing in dim light. Central blurriness may slowly expand, but side (peripheral) vision is usually kept longer. Color contrast can become harder to detect over time.
Classic adult-onset
Vision problems begin in midlife with gradual central blur and need for brighter light. People may notice distorted lines or a gray spot in the center when looking straight ahead. Night driving can become challenging earlier than expected.
Faster-progressing course
Central vision declines over a few years rather than decades. Reading and detailed tasks become difficult sooner, and magnification may be needed early. Regular follow-up is important to track changes and adapt low-vision supports.
Slower-progressing course
Central changes move more gradually, sometimes remaining mild for a long stretch. People may function well with good lighting and contrast aids for many years. Not everyone will experience every type.
What genetics can tell you about symptoms
Certain ABCA4 variants tied to age-related macular degeneration 14 can cause earlier central vision blur, trouble reading fine print, and slower dark adaptation. Changes in complement pathway genes (like C3 or CFH) may drive drusen buildup, leading to distortion, faded colors, and blank central spots.
Causes and risk factors
Key risk factors for Age related macular degeneration 14 include older age, a family history, and certain inherited gene changes. White ancestry and light eye color are linked with higher risk in some groups. Smoking is the strongest lifestyle risk, and high blood pressure, high cholesterol, and obesity add to it. A diet low in leafy greens and fish and little physical activity may also raise risk. Doctors distinguish between risk factors you can change and those you can’t.
Environmental and biological risk factors
Age-related macular degeneration (AMD) tends to show up later in life and can make reading, driving, or recognizing faces harder over time. Some risks are carried inside the body, others come from the world around us. Many of these risks build up long before early symptoms of age-related macular degeneration are noticed. Below are key environmental and biological factors that may raise the chance of AMD.
Risk increases as the eye’s repair systems naturally slow over the years. Aging tissues in the macula become more vulnerable to stress and wear.
Sustained high pressure can strain the delicate vessels that feed the macula. Over time, this can reduce the eye’s ability to clear waste and repair.
Conditions that harden or narrow arteries, including high cholesterol, can limit oxygen and nutrient flow to the back of the eye. Reduced circulation may raise AMD risk and speed changes once present.
Ongoing low-grade inflammation in the body can over-activate defense pathways that affect the retina. This can make the macula more prone to injury from everyday stressors.
Genetic risk factors
Family patterns can make Age related macular degeneration 14 feel personal, especially if several relatives have vision changes. Most cases reflect many genes working together, and this subtype points to a specific inherited change that can tilt risk higher. These genetic influences affect how the retina and its support system handle inflammation and waste removal. Risk is not destiny—it varies widely between individuals.
Subtype variant: In some families, a single inherited change defines age related macular degeneration 14 and marks a higher chance of disease. If this change is known in a family, genetic testing for age related macular degeneration 14 can confirm who carries it. Test results show risk, not certainty.
Complement pathway genes: Common variants in immune-complement genes can tilt the eye’s defense system toward more inflammation. Examples include CFH, C3, C2/CFB, CFI, and C9. These raise risk but do not determine whether AMD appears.
ARMS2/HTRA1 region: Changes in a gene region near ARMS2 and HTRA1 are among the strongest common genetic risks for AMD. This region affects how the retina handles stress and tissue maintenance. These same variants can also influence disease progression.
Rare high-impact changes: Uncommon variants in complement or other retinal support genes can have a larger effect than common ones. These may lead to earlier onset or more severe findings within affected families. Such variants are usually identified through specialized genetic testing.
Family history clues: Having a parent or sibling with AMD suggests shared inherited risk. Clustering across generations can point to age related macular degeneration 14 in families with a known subtype variant. Still, relatives can be affected at different ages and severities.
Polygenic risk score: Dozens to hundreds of small DNA changes can add up to a higher overall risk. Research-based polygenic scores attempt to estimate this, but they do not diagnose AMD. Their use in routine care for age related macular degeneration 14 is still limited.
Ancestry-linked variants: The frequency of certain risk variants differs by ancestry, which shifts average inherited risk between populations. This helps explain why some groups show higher or lower rates of AMD despite similar ages. Individual risk still depends on your own genetic mix.
Incomplete penetrance: Not everyone who carries a risk variant will develop age related macular degeneration 14. Carrying a genetic change doesn’t guarantee the condition will appear. Other genetic factors modify how strongly a variant acts.
Lifestyle risk factors
Here’s how everyday habits can influence your eyes. This overview focuses on lifestyle risk factors for Age related macular degeneration and how habits can influence progression and vision outcomes. Modifying these factors may help slow disease advancement and protect remaining vision.
Cigarette smoking markedly increases AMD risk and speeds progression by promoting oxidative stress. Quitting lowers risk over time and may slow further vision loss.
Diets low in leafy greens, colorful produce, and fish reduce carotenoids and omega‑3s that support the macula. A nutrient-dense eating pattern may slow AMD progression and support retinal function.
Frequent intake of refined carbohydrates spikes blood sugar and may accelerate retinal oxidative damage. Choosing lower‑glycemic carbs can reduce AMD onset and progression risk.
A sedentary routine is linked to poorer vascular health and faster AMD progression. Regular moderate aerobic activity may improve ocular blood flow and help preserve visual function.
Risk prevention
Small, steady steps can lower your chances of age-related macular degeneration (AMD) or slow it down if it’s already present. Prevention is about lowering risk, not eliminating it completely. Focus on eye-safe habits, heart-healthy living, and regular check-ups to catch changes early. If you notice new vision symptoms—like a blurry center when reading or a wavy line—schedule an eye visit promptly.
Get a comprehensive dilated eye exam every 1–2 years, especially after age 50 or if you have family history. Early detection lets doctors step in before major vision loss.
Smoking is the strongest known modifiable risk for AMD. Stopping now lowers risk over time and helps protect the retina’s blood supply.
Wear UV400 sunglasses and a brimmed hat in bright sun. Shielding your eyes may reduce light-related stress on the macula.
Eat spinach, kale, and other colorful vegetables plus fatty fish like salmon 1–2 times weekly. These foods provide lutein, zeaxanthin, and omega‑3s that support macular health.
Transmission
Age related macular degeneration 14 is not contagious—you can’t catch it from someone or pass it on through everyday contact. Instead, it reflects an inherited tendency: certain gene changes can be passed down in families and may increase the chance of macular degeneration as you get older. Because many genes and life factors are involved, this isn’t a simple yes-or-no inheritance; having a parent or sibling with the condition raises risk, but many people with a family history never develop it. If you’re wondering how Age related macular degeneration 14 is inherited, think of the genetic transmission of Age related macular degeneration 14 as passing along risk, not the disease itself, with age, smoking, and overall health also shaping whether and when it appears.
When to test your genes
Test your genes if you have a strong family history of vision loss from macular degeneration, especially if symptoms began before age 60. Consider testing when planning prevention or treatment, since results can refine risk estimates and guide monitoring, supplements, and lifestyle choices. Discuss timing with an eye specialist or genetic counselor.
Diagnosis
You might notice small changes in daily routines, like needing brighter light for reading or finding that faces look blurry in the center. These everyday clues often lead to an eye exam for Age related macular degeneration 14. Getting a diagnosis is often a turning point toward answers and support. If you’re wondering how Age related macular degeneration 14 is diagnosed, it usually starts with a careful history and a detailed look at the back of the eye, followed by imaging tests to map any changes.
Your eye doctor asks about vision changes, lighting needs, and how long symptoms have been present. A detailed family and health history can help connect patterns and risk factors.
Reading letters on a chart measures how clearly you see at different distances. Changes over time help show whether central vision is getting worse.
You look at a simple grid to spot wavy, blank, or distorted areas in central vision. These findings can point toward macular involvement.
Drops widen the pupils so the doctor can examine the macula and retina with special lenses. They look for drusen, pigment changes, bleeding, or fluid that suggest AMD activity.
Stages of Age related macular degeneration 14
Age-related macular degeneration (AMD) typically progresses through defined stages that reflect changes in the center of vision over time. People often ask about early symptoms of age-related macular degeneration, such as needing more light or noticing a blurry spot when reading. Different tests may be suggested to help confirm the stage and track changes, including careful eye exams and retinal imaging.
Early AMD
Often no symptoms are noticed in day-to-day life. An eye exam may show small yellow deposits (drusen) and mild pigment changes. Vision is usually normal, so regular checkups matter.
Intermediate AMD
You may need brighter light to read and have mild blur or more trouble in dim settings. Eye exams show larger or more deposits and changes in the macula. The chance of progressing increases, so closer monitoring is common.
Late dry AMD
Central vision may develop blank or dim areas and colors can look less vivid. The light-sensing layer thins in patches, causing permanent spots of vision loss. Side vision usually remains.
Late wet AMD
Central blur or distortion can worsen quickly, and straight lines may look wavy with new dark spots. Fragile new blood vessels leak under the macula, speeding damage. Prompt treatment is often needed to protect remaining vision.
Outlook and prognosis
Looking at the long-term picture can be helpful. For many people with Age related macular degeneration, vision changes happen slowly over years, especially in the more common “dry” form. You might notice dimmer reading light, needing more contrast, or a blurry spot in the center that makes faces harder to recognize. Even though it can feel overwhelming, treatments and low-vision tools can help people keep doing everyday tasks with adaptations like brighter lighting, magnifiers, larger text, and good glare control.
Doctors call this the prognosis—a medical word for likely outcomes. In dry AMD, vision often declines gradually, and many people keep enough side vision to move around safely and manage daily routines. A smaller group develop “wet” AMD, which can cause faster central vision loss from leaky blood vessels; timely injections can slow or stabilize this in many cases. Mortality is not directly increased by AMD itself, but the condition can raise fall risk and limit independence, so planning for home safety and support matters.
The outlook is not the same for everyone, but early care can make a real difference in preserving sight. Regular eye exams, not smoking, controlling blood pressure, and using AREDS2 supplements when recommended are linked to slower progression. If you’re wondering about early symptoms of Age related macular degeneration and what they mean for your future vision, an Amsler grid at home plus prompt evaluation of any new distortion, dark spots, or sudden blur is key. Talk with your doctor about what your personal outlook might look like, including whether your AMD is dry or wet, how active it is, and which treatments or low‑vision services could help you stay independent.
Long-term effects
Over time, age-related macular degeneration can change how clearly you see straight ahead, making detailed tasks harder. Long-term effects vary widely, and some people notice slow changes while others experience more rapid shifts. For many, AMD affects everyday activities like reading, recognizing faces, or driving at night. Doctors often describe these as long-term effects or chronic outcomes.
Fine detail fades in the center of what you see, while side vision usually stays. This can make reading print, recognizing faces, and seeing small objects difficult.
Straight edges may look bent or rippled. This distortion can make door frames, tiles, or text lines appear uneven.
Words may blur, break apart, or disappear in the center. You may lose your place or need larger, high-contrast print to follow along.
Dim rooms, dusk, or night driving can feel challenging. Moving from bright to dim settings may take longer for your eyes to adjust.
How is it to live with Age related macular degeneration 14?
Living with age-related macular degeneration (AMD) often means central vision becomes blurry or blank while side vision stays, so reading fine print, recognizing faces, and driving—especially at night—can turn from effortless to exhausting. Many adapt by using brighter lighting, high-contrast settings, magnifiers, and larger screens, and by arranging the home so tasks rely more on peripheral vision. Loved ones may notice you need more time to spot details or navigate new places, and their patient support—like reading labels aloud or offering a steady arm in dim light—can make daily life smoother. For many, staying engaged with low-vision rehab, routine eye care, and community resources preserves independence and keeps hobbies and connections within reach.
Treatment and drugs
Treatment for age-related macular degeneration is tailored to the type you have—dry (more common) or wet (less common but faster-changing). For dry age-related macular degeneration, care focuses on protecting vision over time: stopping smoking, managing blood pressure, using good lighting, and in some cases taking specific eye vitamins (AREDS2 formula) that may slow progression in intermediate disease; regular eye checks and home Amsler grid monitoring help catch changes early. Wet age-related macular degeneration is treated with injections into the eye of medicines that block abnormal blood vessel growth (anti-VEGF drugs), often given every 4–12 weeks at first and then spaced out based on how your retina looks and how you’re seeing; a few centers may use a tiny refillable implant or occasional laser or photodynamic therapy in selected cases. Supportive care can make a real difference in how you feel day to day, including low-vision aids, vision rehabilitation, and apps or devices that enlarge print and improve contrast for reading and daily tasks. Ask your doctor about the best starting point for you, and how often you’ll need monitoring, since treatment plans often combine several approaches and may change as your eyes change.
Non-drug treatment
Non-drug care can help slow changes, protect day-to-day vision, and make reading, driving, and home tasks easier for people living with age-related macular degeneration. Non-drug treatments often lay the foundation for long-term eye health and can work alongside any medical procedures your specialist recommends. These steps won’t reverse damage, but they can reduce the chance of progression and help you use the vision you have. Your eye team can tailor choices based on whether AMD is early, intermediate, or advanced.
Stopping smoking is one of the most powerful ways to slow AMD progression. It improves blood flow to the retina and lowers ongoing damage. Ask your doctor about quit programs, nicotine replacement, or counseling for support.
For intermediate AMD or advanced AMD in one eye, the AREDS2 formula may lower the risk of further vision loss. It is not shown to help in early AMD and should be the AREDS2 version (without beta-carotene) for current or former smokers. Discuss the exact formulation and dosing with your eye specialist.
A Mediterranean-style pattern emphasizing leafy greens, colorful vegetables, legumes, whole grains, and fish is linked to slower AMD changes. Food sources of omega-3s (like salmon or sardines) are preferred over supplements, which haven’t shown clear AMD benefit. Limiting ultra-processed foods and refined sugars supports overall eye and heart health.
Brisk walking, cycling, or swimming most days can support retinal circulation and reduce inflammation. Aim for at least 150 minutes a week of moderate activity, adjusted to your abilities. Even short, frequent walks add up.
Your genes may have an impact on how drugs work for you
Genes can affect how well AMD treatments like anti-VEGF injections work and how likely you are to have side effects. Variants in pathways controlling inflammation, complement activity, and drug processing can change response, dosing needs, and long‑term outcomes.
Pharmacological treatments
Treatments for age-related macular degeneration (AMD) aim to protect vision, reduce fluid or bleeding in wet AMD, and slow retinal damage in geographic atrophy. Most medicines are given as quick injections into the eye during a clinic visit; the timing varies from monthly to every few months. Not everyone responds to the same medication in the same way. Your eye specialist will tailor the plan over time, balancing vision gains with convenience and safety.
This anti-VEGF injection (Lucentis) helps dry up leaking blood vessels in wet AMD and can improve or stabilize vision. It is often given monthly at first, then spaced out if the eye stays dry.
This anti-VEGF medicine (Eylea) is commonly used for wet AMD to control fluid and bleeding. After a few starter doses, many people switch to every 4–8 weeks, sometimes longer if the retina remains stable.
This anti-VEGF drug (Avastin) is used off-label for wet AMD and has shown similar vision outcomes to other options in many studies. It is typically given every 4–6 weeks at first, with spacing adjusted based on retinal scans.
This anti-VEGF option (Beovu) can allow longer intervals between injections for some people. Rarely, it can cause eye inflammation or blocked retinal vessels, so close monitoring is important.
Genetic influences
Research shows that inherited factors play a major role in this condition. In Age related macular degeneration 14 (often shortened to AMD), several common gene changes raise or lower risk by affecting how the eye handles inflammation and clears cell waste. Many of these changes act like dimmer switches, nudging risk rather than flipping it on or off. Family history is one of the strongest clues to a genetic influence. Having a parent or sibling with AMD roughly doubles to triples your chances, but lifestyle factors such as smoking and diet still make a big difference. Today’s DNA tests can spot some of these risk variants, yet they can’t predict who will develop vision loss or when, and results rarely change day-to-day care.
Is Age related macular degeneration 14 genetic?
Genetics play a major role in Age related macular degeneration 14; several inherited variants strongly increase risk. Family history raises the chance of developing it earlier or more severely. Still, lifestyle and environmental factors also influence onset and progression.
Pharmacogenetics—how genetics influence drug effects
For people being treated for macular degeneration, including Age related macular degeneration 14, your genes may shape how your eye responds to certain therapies, but they rarely change which medicines are recommended right now. Not every difference in response is genetic, but differences in genes that affect blood vessel growth or the immune “complement” system may partly explain why some people need more injections or improve more slowly. Studies looking for gene markers to predict who will do best with anti-VEGF injections have found mixed results, so routine genetic testing isn’t used to pick a specific drug or dose. The same applies to eye vitamins (AREDS2): current evidence doesn’t support changing the formula based on genetic test results. Newer treatments that target the complement pathway for geographic atrophy are also being studied for gene–drug interactions, yet there’s no proven way to match them to your DNA in day-to-day care. If you’re curious about pharmacogenetic testing in age-related macular degeneration, talk with your eye specialist about whether any results would change your treatment plan today.
Interactions with other conditions
On busy days, people notice their reading or screen work gets tougher if their blood pressure is up or their blood sugar is off, and the glare from lights seems harsher than usual. Doctors call it a “comorbidity” when two conditions occur together. In Age related macular degeneration 14, high blood pressure, heart disease, and high cholesterol often travel alongside the eye disease; these can affect blood vessels and inflammation, and good control of them supports overall eye health and may help slow progression of Age related macular degeneration 14. Diabetes and diabetic eye disease can add swelling or bleeding in the retina, so regular checkups with both the eye clinic and diabetes team are important to sort out which changes come from which condition. Cataracts and glaucoma also commonly appear with aging; cataract surgery generally does not speed up AMD and often improves vision from the cataract, while glaucoma needs ongoing pressure checks because vision loss from each condition can add up. Coordinated care—sharing plans and medication lists among your eye specialist, primary doctor, and any heart or diabetes teams—helps avoid drug interactions and keeps monitoring on track.
How genes can cause diseases
Humans have more than 20,000 genes, each carrying out one or a few specific functions in the body. One gene instructs the body to digest lactose from milk, another tells the body how to build strong bones and another prevents the body's cells from beginning to multiply uncontrollably and developing into cancer. As all of these genes combined are the building instructions for our body, a defect in one of these genes can have severe health consequences.
Through decades of genetic research, we know the genetic code of any healthy/functional human gene. We have also identified that in certain positions on a gene, some individuals may have a different genetic letter from the one you have. We call these hotspots "Genetic Variations" or "Variants" in short. In many cases, studies have been able to show that having the genetic letter "G" in the position makes you healthy, but having the letter "A" in the same position disrupts the gene function and causes a disease. Genopedia allows you to view these variants in genes and summarizes all that we know from scientific research, which genetic letters (Genotype) have good or bad consequences on your health or on your traits.
History
Throughout history, people have described trouble seeing fine detail with age—threading a needle becomes difficult, faces look blurred across the room, and straight lines on a page may seem wavy. Families and communities once noticed patterns: older relatives needing brighter light and magnifiers, or avoiding night driving because central vision no longer felt reliable. These everyday experiences echo what we now call age-related macular degeneration (AMD).
First described in the medical literature as “senile macular degeneration” in the late 1800s and early 1900s, early accounts focused on the noticeable loss of sharp central vision while side vision stayed mostly intact. Doctors drew the retina by hand and noted yellow spots under the center of the retina, later named drusen. Initially understood only through symptoms, later observations connected these spots with gradual vision changes, especially in people over 60.
As medical science evolved, new tools changed the picture. The ophthalmoscope allowed doctors to see the back of the eye in living patients. Fluorescein angiography in the mid-20th century outlined leaking blood vessels under the macula and helped distinguish “dry” from “wet” forms. With each decade, imaging grew more precise. Optical coherence tomography (OCT) in the 1990s and 2000s provided cross-sectional “slices” of the retina, revealing fluid, thinning, and deposits in remarkable detail and allowing earlier detection of subtle, early symptoms of age-related macular degeneration.
Understanding also shifted from simply “aging eyes” to a complex condition shaped by genes, environment, and lifestyle. In recent decades, knowledge has built on a long tradition of observation. Large population studies linked smoking, high blood pressure, and diet to risk. Advances in genetics identified common variants—especially in immune and complement pathways—that influence susceptibility, explaining why some families see more AMD across generations while others do not. These discoveries reframed AMD as a condition where the retina’s support systems gradually falter, and in some people, abnormal new vessels grow and leak.
Treatment history reflects these milestones. For much of the 20th century, options were limited to magnifiers and lighting. Laser therapy offered modest, targeted help for some “wet” AMD cases. A major shift came in the mid-2000s with anti-VEGF injections, medicines that block signals driving leaky vessel growth. For many living with wet AMD, this changed the outlook from rapid loss of central vision to stabilization—and often improvement—when treatment is started promptly. Alongside medical treatments, low-vision rehabilitation has steadily expanded, helping people make the most of their remaining sight.
Over time, the way the condition has been understood has changed, moving from sketches and symptom notes to high-resolution scans and tailored therapies. Today’s approach to age-related macular degeneration builds on more than a century of careful observation, and it continues to evolve as imaging, genetics, and treatment advance.